Benzinga

España
Italia
대한민국
日本
Français
Benzinga Edge
Benzinga Research
Benzinga Pro

  • Get Benzinga Pro
  • Data & APIs
  • Events
  • Premarket
  • Advertise
Contribute
España
Italia
대한민국
日本
Français

Benzinga

  • Premium Services
  • Financial News
    Latest
    Earnings
    Guidance
    Dividends
    M&A
    Buybacks
    Interviews
    Management
    Offerings
    IPOs
    Insider Trades
    Biotech/FDA
    Politics
    Healthcare
    Small-Cap
  • Markets
    Pre-Market
    After Hours
    Movers
    ETFs
    Options
    Cryptocurrency
    Commodities
    Bonds
    Futures
    Mining
    Real Estate
    Volatility
  • Ratings
    Analyst Color
    Downgrades
    Upgrades
    Initiations
    Price Target
  • Investing Ideas
    Trade Ideas
    Long Ideas
    Short Ideas
    Technicals
    Analyst Ratings
    Analyst Color
    Latest Rumors
    Whisper Index
    Stock of the Day
    Best Stocks & ETFs
    Best Penny Stocks
    Best S&P 500 ETFs
    Best Swing Trade Stocks
    Best Blue Chip Stocks
    Best High-Volume Penny Stocks
    Best Small Cap ETFs
    Best Stocks to Day Trade
    Best REITs
  • Money
    Investing
    Cryptocurrency
    Mortgage
    Insurance
    Yield
    Personal Finance
    Forex
    Startup Investing
    Real Estate Investing
    Prop Trading
    Credit Cards
    Stock Brokers
Research
My Stocks
Tools
Free Benzinga Pro Trial
Calendars
Analyst Ratings Calendar
Conference Call Calendar
Dividend Calendar
Earnings Calendar
Economic Calendar
FDA Calendar
Guidance Calendar
IPO Calendar
M&A Calendar
Unusual Options Activity Calendar
SPAC Calendar
Stock Split Calendar
Trade Ideas
Free Stock Reports
Insider Trades
Trade Idea Feed
Analyst Ratings
Unusual Options Activity
Heatmaps
Free Newsletter
Government Trades
Perfect Stock Portfolio
Easy Income Portfolio
Short Interest
Most Shorted
Largest Increase
Largest Decrease
Calculators
Margin Calculator
Forex Profit Calculator
100x Options Profit Calculator
Screeners
Stock Screener
Top Momentum Stocks
Top Quality Stocks
Top Value Stocks
Top Growth Stocks
Compare Best Stocks
Best Momentum Stocks
Best Quality Stocks
Best Value Stocks
Best Growth Stocks
Connect With Us
facebookinstagramlinkedintwitteryoutubeblueskymastodon
About Benzinga
  • About Us
  • Careers
  • Advertise
  • Contact Us
Market Resources
  • Advanced Stock Screener Tools
  • Options Trading Chain Analysis
  • Comprehensive Earnings Calendar
  • Dividend Investor Calendar and Alerts
  • Economic Calendar and Market Events
  • IPO Calendar and New Listings
  • Market Outlook and Analysis
  • Wall Street Analyst Ratings and Targets
Trading Tools & Education
  • Benzinga Pro Trading Platform
  • Options Trading Strategies and News
  • Stock Market Trading Ideas and Analysis
  • Technical Analysis Charts and Indicators
  • Fundamental Analysis and Valuation
  • Day Trading Guides and Strategies
  • Live Investor Events
  • Pre-market Stock Analysis and News
  • Cryptocurrency Market Analysis and News
Ring the Bell

A newsletter built for market enthusiasts by market enthusiasts. Top stories, top movers, and trade ideas delivered to your inbox every weekday before and after the market closes.

  • Terms & Conditions
  • Do Not Sell My Personal Data/Privacy Policy
  • Disclaimer
  • Service Status
  • Sitemap
© 2026 Benzinga | All Rights Reserved
August 10, 2021 3:51 PM 2 min read

SmileDirectClub Stock Tumbles After Q2 Earnings: Is The Growth Story Broken?

by Wayne Duggan Benzinga Staff Writer
Follow

SmileDirectClub Inc (NASDAQ:SDC) shares dropped 22.6% on Tuesday after the company reported disappointing second-quarter numbers following an April cyberattack.

On Monday, SmileDirectClub reported a second-quarter adjusted EPS loss of 14 cents on $174 million in revenue. Both numbers fell short of analyst expectations of a 10-cent loss on revenue of $198.5 million. Revenue was up 62.7% from a year ago.

Related Link: 7 Uber Analysts Break Down Q2 Earnings: 'Risk Is Passing And Stock Oversold'

SmileDirectClub reported 90,006 unique aligner shipments in the quarter and an average aligner gross sales price of $1,885, up from $1,817 a year ago.

Management said SmileDirectClub is dealing with near-term headwinds from an April cyberattack and a lingering COVID-19 impact on the company’s target demographic of customers.

Looking ahead, SmileDirectClub guided for full-year revenue of between $750 million and $800 million. Management said sales and marketing costs as a percentage of total revenue will be between 50% and 55% through the second half of 2021.

Voices From The Street: Goldman Sachs analyst Nathan Rich said SmileDirectClub will likely continue to burn another $219 million in cash through the end of 2022 as it deals with competitive challenges that weighed on results in the second quarter.

“While SDC believes these impacts are near-term and reaffirmed its 5-year targets of 20-30% topline growth and 25-30% adj. EBITDA margins, we think the 2Q update demonstrates the challenges of driving revenue growth while expanding margins,” Rich wrote.

JPMorgan analyst Robbie Marcus said SmileDirectClub is facing structural headwinds and an unclear path to long-term profitability.

“Given the impaired near-term revenue trajectory, and what could be structurally higher costs, we see better opportunities in our coverage universe,” Marcus wrote.

Stephens analyst Chris Cooley said SmileDirectClub has plenty of brand value and market share, but recent missteps make the stock a show-me story for now.

“While we acknowledge the share's ~70% relative discount multiple and expect the shares to open lower on the news, we are stepping aside due to continued concern related to risks related to revised CY21 guidance and the perceived increasing fluidity of focus in the business model most likely resulting in the shares remaining range-bound until consistent execution of the business plan and corporate guidance is exhibited,” Cooley wrote.

Ratings And Price Targets:

  • Goldman Sachs has a Sell rating and a $4 target.
  • JPMorgan has an Underweight rating and a $6 target.
  • Stephens has an Equal Weight rating and $11 target.

Photo: SmileDirectClub

Market News and Data brought to you by Benzinga APIs

© 2026 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

To add Benzinga News as your preferred source on Google, click here.


Posted In:
Analyst ColorEarningsNewsHealth CarePrice TargetSmall CapAnalyst RatingsGeneralGoldman SachsJPMorganStephens
Beat the Market With Our Free Pre-Market Newsletter
Enter your email to get Benzinga's ultimate morning update: The PreMarket Activity Newsletter
Comments
Loading...